Background: Serum copper not bound to ceruloplasmin ("free") appears slightly elevated in patients with Alzheimer disease (AD). We explored whether a deregulation of the free copper pool can predict AD clinical worsening.
among albumin, amino acids (e.g., histidine), and small molecular weight complexes (0.5-5%; normal value Ͻ1.6 mol/L), 5 which can easily cross the blood-brain barrier (BBB). 6 Most studies of diagnostic markers focus on the early diagnosis of AD. Fewer studies have aimed at the identification of prognostic markers that influence the variation in rate of decline after patients have received the diagnosis of AD and little is known about the determinants of the variability.
In this study, we explored the hypothesis that a deregulation of the free copper pool in serum could be a determinant of the variability of the progression of cognitive decline in a group of patients with mild or moderate AD. METHODS A total of 107 patients with probable AD according to National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association, 7 showing mild or moderate cognitive impairment (score Յ2 of the Clinical Dementia Rating) 8 and a Mini-Mental State Examination (MMSE) 9 score of 25 or less (range 16 -24) , were recruited in two specialized dementia care centers: the Department of Neuroscience, Fatebenefratelli Hospital, Isola Tiberina, Rome, Italy, and the IRCCS, Fatebenefratelli Hospital of Brescia, Italy.
Criteria for exclusion were conditions known to affect copper metabolism and biologic variables of oxidative stress on the basis of the past medical history and screening laboratory tests, reported in detail elsewere. 1 We also excluded patients with a history of stroke, presence of focal neurologic signs, severe subcortical leukoencephalopathy, presence of hemodynamically significant neck and intracranial arteries stenosis or occlusion, or cardiopathy.
When admitted to the study, patients underwent a structured clinical interview, a neurologic examination, brain MRI, an extensive neuropsychological assessment, biochemical measurements, and apolipoprotein E (APOE) genotyping. Blood was drawn on the same day of the clinical interview. Follow-up was performed 12 months after inclusion in the study. During this period, patients received the acetylcholinesterase inhibitor donepezil (5 mg daily for 3 months and then 10 mg daily) and compliance to the therapy was checked periodically by means of telephone contacts and visits performed at 3-month intervals.
Progression of cognitive decline was evaluated by means of the MMSE (primary outcome) and activities of daily living (ADL) and instrumental activities of daily living (IADL) (secondary outcomes) performed at study entry and at the end of the follow-up period.
The study was approved by the local ethical committee. All patients or caregivers gave written consent to be included in the study.
Biochemical and molecular investigations. Patients' fasting blood samples were collected in the morning and serum was rapidly stored at Ϫ80°C. Serum copper concentration was estimated following the method of Abe et al. (Randox Laboratories, Crumlin, UK) 10 and by an A Analyst 300 Perkin Elmer atomic absorption spectrophotometer equipped with a graphite furnace with platform HGA 800 (Foster City, CA). 11 Ceruloplasmin was analyzed by immunoturbidimetry assay (Horiba ABX, Montpellier, France). 12 For each serum copper and ceruloplasmin pair we computed the amount of copper bound to ceruloplasmin (CB) and the amount of copper not bound to ceruloplasmin (free copper) following standard procedures (appendix 1 of reference 5: "Calculation of 'free copper' concentration") 5 ; briefly: CB ϭ ceruloplasmin (mg/dL) ϫ 10 ϫ n; n ϭ 0.0472 (mol/mg); free copper ϭ absolute serum copper Ϫ CB. 5 This calculation expresses free copper in mol/L and is based on the notion that ceruloplasmin contains 0.3% copper. 5 Thus, for a patient with a serum absolute (or total) copper concentration of 17.3 mol/L and a serum ceruloplasmin concentration of 33 mg/dL, the bound copper concentration ϭ 33 ϫ 10 ϫ 0.0472 ϭ 15.6 mol/L, and the free copper concentration ϭ 17.3-15.6 ϭ 1.7 mol/L. Moreover, we have recently set up an automated procedure to measure ceruloplasmin oxidase activity which utilizes o-diansidine dihydrochloride as a substrate, according to previous methods. 13, 14 In fact, it is well known that values of ceruloplasmin obtained immunologically, as we showed them in this study, result in higher values than those obtained enzymatically, i.e., monitoring the protein's oxidase activity. 5, 13, 14 This is because the apo-form of ceruloplasmin is biologically inactive. 5 In normal controls, the two detection methods showed a significant correlation (data not shown), as also reported by other authors. 5, 13, 14 However, quantification of ceruloplasmin by the enzymatic method based on standard ceruloplasmin solutions has not been considered by the majority of previous authors, 13 because of its cost, the variable purity of commercially available ceruloplasmin, and the general recommendation to report serum enzymes in International Units. 13 We have tried to quantify the amount of ceruloplasmin starting from the protein's oxidase activity with a commercial standard (Human Serum Ceruloplasmin, Sigma-Aldrich), but the spectroscopic inspection of the latter revealed a decay in the protein peak of absorbance in dayto-day assays (data not shown), decreasing our confidence in using the enzymatic detection to quantify the protein amount, necessary to estimate the free copper value.
Measurements of the other biologic variables of oxidative stress are described in detail elsewhere. 15 Briefly, hydro-peroxide content was assessed by d-ROMs test (Diacron, Italy) and expressed in arbitrary units (U.CARR), 1 U.CARR corresponding to 0.08 mg/100 mL of hydrogen peroxide. Normal range was between 230 and 310 U.CARR. 16 Total radical trapping antioxidant capacity, or TRAP, was assayed by the TAS kit (Randox Laboratories, Crumlin, UK), based on published methods. 17 The serum reference range is 1.30 -1.77 mmol/L. 17 Transferrin level was analyzed by immunoturbidimetry assay, 18 and iron using Ferene. 19 All these reagents were ABX Pentra from Horiba ABX (Montpellier, France). Zinc levels were measured using the specific complexant 5- 20 according to manufacturer's instructions (Zinc, Sentinel Diagnostic, Milan, Italy).
All biochemical measures were automated on a Cobas Mira Plus (Horiba abx, Montpellier, France) and performed in duplicate.
APOE genotyping was performed according to standard methods. 21 MRI evaluation. Brain MRI was performed using a 1.5 Tesla superconductor magnet. The imaging protocol consisted of axial T2 W double spin echo sequences and T1 W spin echo images in axial, coronal, and sagittal planes, with 5 mm slice thickness and intersection gap ϭ 0.5 mm. An extensive MRI evaluation was performed (data not shown). Briefly, the spin echo technique and T1 W, T2 W, and fluid-attenuated inversion-recovery sequences detected pos-sible white matter lesions. These were graded according to published protocols. 22 Only patients without vascular lesions (grade 0) or with small subcortical focal lesions defined as high signal intensity areas on T2-weighted images, but isointense with normal brain parenchyma on T1-weighted images and classified as grade I (44.5%; table 1), were included. Volumetric analysis of the hippocampus was visually performed by scoring every patient according to the width of the choroid fissure and the temporal horn, following the criteria of a rating scale of temporal lobe atrophy previously reported (five point rating scale of medial temporal lobe atrophy [MTA]). 1, 22 MRI revealed that atrophy of the medial temporal lobes with a reduction in hippocampal volume (score 2-4) was prominent (71%; table 1) in the patients.
Statistical analyses. Formal sample size calculation was not performed because this was an exploratory study of possible correlation between metal and oxidative biologic variables and impairment and severity of progressive cognitive decline. However, we considered as relevant a bivariate correlation of 0.40 (corresponding to 16% of accounted variance) and calculated that a sample size of 50 patients would result in a power of 86% (with bilateral ␣ at 0.05).
The aim of the study was to see whether and how severe the progression of cognitive decline was in relation to metal and oxidative biologic variables alterations. Attaining this goal was best served by a regression model. A multiple regression analysis was applied to test the potential confounding role of demographic characteristics (sex, age, and education) and vascular risk factors (hypertension, smoking habits, and hyperlipidemia), then the linearity of the relationship between metal and oxidative biologic variables alterations and severity of progression of cognitive impairment was tested using a polynomial regression and the best-fitting model (maximum R 2 and significant R 2 change vs the previous model) was chosen.
To provide additional information potentially useful for clinicians, outcome cognitive variables were dichotomized in two groups: above or equal to 3 points MMSE decrease (severe cognitive decline) and below 3 (milder cognitive decline). Impairment was evaluated using a logistic regression model. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated.
RESULTS
Patients. Eighty-one of the 107 subjects completed the follow-up after 1 year. The main baseline demographic and medical characteristics of these patients are reported in table 1, along with evaluations of free copper and MMSE at baseline and at the 1 year follow-up. Patients were affected mainly by hypertension (36%), cardiopathy (9%), hyperlipidemia (13%), diabetes (11%), and smoking (33%). The most frequent drugs taken by patients were antiplatelet aggregation agents (43%), statins (24%), and antihypertensive drugs (39%), mostly represented by calcium antagonist (17%). During the study, all patients received acetylcholinesterase inhibitors. Allele APOE 4 frequency was 24.5%. The APOE 4 allele was more prevalent in patients born in northern Italy (35%) than in central/southern Italy (17%; p ϭ 0.013). Patients at baseline had mild to moderate dementia (MMSE: mean ϭ 20.5, SD ϭ 3.5).
Sixty-five percent of patients had a higher than normal free copper (Ͻ1.6 mol/L). 5 Patients who were carriers of the APOE 4 allele had higher levels of free copper than noncarriers (data not shown). 11 After 1 year, MMSE decreased by 3.2 points (SD ϭ 3.9; p Ͻ 0.001; table 1).
Prediction of cognitive decline. Baseline cognitive status could be the first predictor of cognitive deterioration. In consideration of this, the annual change in MMSE was adjusted for the baseline MMSE by means of a linear regression model, even though only 4% of change variance was accounted for by baseline measurement. We then analyzed the correlations between cognitive decline at 1 year and the biologic variables under study. The analysis revealed that the higher the annual change in MMSE, the higher both 
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Calcium antagonists 17 the absolute copper and free copper ( indicating that about 3 mol/L units of free serum copper explained a one-point loss on the annual change in the MMSE. To better quantify our model the analysis of influential statistics was applied (based on changes in regression coefficients and on leverage measures): this analysis indicated that the exclusion of outlier cases with a potentially detrimental effect on the regression model did not change the relationship between free copper and MMSE changes (data not shown).
We also observed an effect of hyperlipidemia on cognitive decline. Hyperlipidemia was associated with a 2.6 point loss on the annual change in MMSE. Hyperlipidemia accounted for 4.8% of residual variance (p ϭ 0.058). Hyperlipidemic patients with higher levels of free copper seemed more prone to higher cognitive impairment.
When the annual change in MMSE scores were divided into Ͻ3 or Ն3 points, the multiple logistic regression indicated that free copper was the only predictor of more severe decline; for each additional mol/L unit of free copper, the odds of MMSE worsening increased by about 23% (OR ϭ 1.23; 95% CI ϭ 1.03-1.47; p ϭ 0.022). Those patients from the current study panel who had a value of free copper higher than 2.1 mol/L had an increased probability of worsening than those patients who had their free copper values below such levels ( figure) .
Diabetes had no effect in explaining cognitive decline even after adjusting for free copper values (p Ͼ 0.2).
Drug treatment effects were taken into account in the analysis. Concentrations of free serum copper [t(79) ϭ 3.746; p Ͻ 0.001] and cognitive decline [t(79) ϭ 3.716; p ϭ 0.005] were lower in those patients who were administered with calcium antagonists. When this effect was included in the multiple regression analysis, free copper could not enter the model for prognosis evaluation.
Free copper correlated with the ADL and IADL clinical scales which evaluate the disabilities in daily living of the patients. At baseline, higher levels of free copper corresponded to lower ADL scores at the 1-year evaluation (rho ϭ Ϫ0.299, p ϭ 0.018). The higher were free copper levels, the lower were IADL scores either at baseline (rho ϭ Ϫ0.0349, p ϭ 0.001) or at 1 year (rho ϭ Ϫ0.359, p ϭ 0.004).
DISCUSSION
The most important result of this study suggests that a deregulation of free copper could determine the variability of the progression of cognitive decline in AD. However, the implication of free copper in this disease was based on correlative studies. Therefore, the present study does not allow a conclusive interpretation about a causal pathophysio- logic effect of serum copper abnormalities on cognitive decline. Our current findings show that higher levels of free copper could explain a decline in MMSE scores. In spite of the relatively low percentage of explained variance of free copper, the most interesting aspect of our study is the possibility of obtaining useful information for identification of patients with AD at higher risk for a rapid and pronounced evolution of cognitive impairment by means of a simple blood test. The majority of studies report that there is heterogeneity in the progression of AD. The severity of cognitive impairment at baseline, 23 as well as hippocampal atrophy, 24 are suggested to be important predictors of progression. With regard to those patients with a free copper dysfunction, estimated to be 65% of our patients, a free copper value higher than normal seems to represent a determinant of progression variability. In particular, a value of free copper higher than 2.1 mol/L increased the probability of loss of 3 points in a year on the MMSE. These results are consistent with the hypothesis that even a small increase of the serum low molecular weight copper, i.e., free copper, can be of significance, particularly over a long period of time. In fact, free copper is potentially toxic as it can promote oxidative stress, 25 because this low molecular weight copper can easily cross the BBB and supply the brain with a continuous flux of noxious redox copper. This interpretation is supported by results of an experiment with mice to test the effects of radiocopper [67Cu(II)] brain uptake during a single passage through the telencephalon-diencephalon microcirculation which demonstrates that net brain copper uptake parallels the increase of the free copper level in the injectate, starting from a concentration of Cu (II) of 3.2 ng/mL, corresponding to 0.05 mol/L. 26 In the present study, changes in ADL and IADL-which predict future functional decline, institutionalization, and death-were evaluated in relation to copper status. Patients with higher levels of free copper at baseline seemed to have a faster and more pronounced evolution of disabilities, in parallel with the progression of cognitive decline.
Our data indicate that hyperlipidemia was the only risk factor associated with MMSE worsening. Even though it is relevant in a small number of patients, we demonstrated an interaction between free copper and hyperlipidemia on cognitive decline in agreement with other authors who used different study design approaches. 27, 28 The impact of serum copper on cognitive decline in this study was not affected by age, sex, or education.
We have tried to control confounders by selecting patients with no evidence of additional pathologic conditions, and by taking into account cardiovascular risk and drug treatment. In this patient sample we noted that subjects who were taking a calcium antagonist therapy had lower levels of circulating free copper. A possible explanation is a diminished rate of copper absorption at the intestinal level.
This study has a number of limitations, which include the shortage duration of the clinical followup, the need for patient selection that possibly resulted in sampling bias, and the refusal to perform follow-up evaluation by some patients that reduced the number of subjects initially involved in the study. Another interesting result of this study concerns the possibility that a therapeutic intervention aimed at metal levels could have favorable practical implications for the management of AD. 29 Therapeutic strategies available for copper's diseases, i.e., Wilson disease, at least in a subgroup of patients with AD with impaired copper metabolism, deserve further study.
